血清PSA及PAP测定的临床应用评价

The evaluation of clinical application for measurement of serum PSA and PAP

报道了23例前列腺癌、42例良性前列腺增生及21例男性非前列腺疾病住院患者血清PSA及PAP联合测定结果。前列腺癌组与良性前列腺增生及对照组比较有极显著差异,按决策矩阵法对血清PSA及PAP进行临床综合评价,两者诊断指数和可用度分别为135.8％、138.3％和0.36、0.45。结果表明血清PSA及PAP测定对于前列腺癌诊断及鉴别诊断为互补关系,血清PSA测定作为前列腺癌治疗效果监测指标优于血清PAP则定。

The serum PSA and PAP were measured in 23 cases of prostatic carcinoma, 42 cases of benign prostatic hypertrophy and 21 cases of non-prostatic disease. Significant differences had been found between prostatic carcinoma and benign prostatic hypertrophy or control group. According to the Decision Matrix for general clinical evaluation. The diagnostic index and availability of serum PSA and PAP were 135.8%, 138.3% and 0.36, 0.40, respectively. The study showed that the measurement of the serum PSA and PAP should be complementary each other for the diagnosis and differential diagnosis of prostatic carcinoma. Finally, it was considered that the measurement of the serum PSA is superior to that of PAP for therapeutic follow- up in patients with prostatic carcinoma.